Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.46
    +2.34 (+0.31%)
     

  • GBP/EUR

    1.1667
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2473
    -0.0038 (-0.31%)
     

  • Bitcoin GBP

    50,957.14
    -207.50 (-0.41%)
     

  • CMC Crypto 200

    1,319.68
    -76.85 (-5.50%)
     

  • S&P 500

    5,102.89
    +54.47 (+1.08%)
     

  • DOW

    38,235.87
    +150.07 (+0.39%)
     

  • CRUDE OIL

    83.99
    +0.42 (+0.50%)
     

  • GOLD FUTURES

    2,348.00
    +5.50 (+0.23%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,163.01
    +245.73 (+1.37%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Zealand Pharma to participate in Jefferies Virtual Healthcare Conference

Zealand Pharma
·2-min read

Company announcement – No. 32/ 2021

Zealand Pharma to participate in Jefferies Virtual Healthcare Conference

Copenhagen, DK and Boston, MA, U.S. May 26, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company aspiring to change lives through the development of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies Virtual Healthcare Conference.

Jefferies Virtual Healthcare Conference

Date: Wednesday, June 2, 2021

Presentation: 2:00 p.m. ET/ 7:00 p.m. CET


A live webcast of the event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

ADVERTISEMENT

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development. Zealand markets V-Go®, abasal-bolus insulin delivery option for people with diabetes and has received approval for Zegalogue® (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.


For further information, please contact:

Zealand Pharma Investor Relations

Claudia Styslinger

Argot Partners

investors@zealandpharma.com


Zealand Pharma Media Relations

David Rosen

Argot Partners

media@zealandpharma.com